April 2019 in “Journal of Investigative Dermatology” Surgery and antifungal medication are effective for treating Merkel cell carcinoma with fungal infection.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
July 2022 in “SKIN The Journal of Cutaneous Medicine” A new lotion with halobetasol and tazarotene successfully treats acne keloidalis nuchae.
November 2023 in “Frontiers in pharmacology” Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
27 citations
,
November 1991 in “Journal of Investigative Dermatology” 46 citations
,
April 2020 in “Drugs” Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
16 citations
,
August 2015 in “Journal of Experimental & Clinical Cancer Research” The photolyase-based device significantly changed the size and heat of potential skin cancer areas in patients.
6 citations
,
September 2019 in “Skin pharmacology and physiology” RCS-01 therapy is safe and may improve skin structure by affecting gene expression.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
March 1990 in “Journal of Dermatological Science” 1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
22 citations
,
June 2010 in “Experimental Dermatology” Lower MC2R expression may contribute to alopecia areata.
January 2020 in “VCU Scholars Compass (Virginia Commonwealth University)” Sex hormone antibodies can help identify male and female contributors in forensic samples.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
45 citations
,
March 2001 in “Journal of Investigative Dermatology” A new protein, mK6irs, is found in specific hair layers and may help understand hair growth and diseases.
20 citations
,
February 1968 in “Journal of Histochemistry & Cytochemistry” A new test more accurately detects citrulline in hair follicles and pilomatrixomas.
1 citations
,
September 2023 in “Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)” Avian yolk antibodies offer a promising, ethical alternative for disease prevention and therapy.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
1 citations
,
June 2023 in “JAAD case reports” Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
8 citations
,
June 1981 in “Clinica Chimica Acta” 57 citations
,
August 2023 in “American Journal of Clinical Dermatology” JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.
18 citations
,
December 1992 in “Journal of Cutaneous Pathology” Skin tumors and normal skin structures have different lectin-binding patterns.
January 2002 in “Academic Journal of Kunming Medical College” Human-hair keratin artificial tendons are biocompatible and degrade well in rabbits.
1 citations
,
August 2022 in “Pigment Cell & Melanoma Research” New mouse models help study melanocytic cells for melanoma research.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
January 2000 in “Acta Academiae Medicine Militaris Tertiae” Different keratins in hair follicles can help identify hair tumor origins.
17 citations
,
January 2015 in “Dermatology online journal” A patient's grey hair regained color during treatment with adalimumab.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
CD28 is a promising target for treating alopecia areata with belatacept.